The Indian pharmaceutical industry is the world's second-largest by volume and is likely to lead the manufacturing sector of India. India's bio-tech industry clocked a 17 percent growth with revenues of 
137 billion ($3 billion) in the 2009-10 financial year over the previous fiscal. Bio-pharma was the biggest contributor generating 60 percent of the industry's growth at 8,829 crore, followed by bio-services at 2,639 crore and bio-agri at 1,9According to data published by the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, the total turnover of India's pharmaceuticals is expected to reach $ 55 billion in 2020 from $ 12.6 billion in 2009. The report also states that the market has the further potential to reach $ 70 billion by 2020 in an aggressive growth scenario.
Indian pharmaceutical companies like Glenmark, Aurobindo and Sun Pharma have not only carved a niche in the Indian market but also the U.S. as well. According to a report, they have bagged about 33 percent or 139 of 419 original Abbreviated New Drug Application (ANDA) approvals from the U.S. Food and Drug Administration (FDA) in 2010. These companies have bagged the first position in the U.S. generic market. Generics is the process of manufacturing cheaper versions of branded and patented drugs.
Glenmark Generics U.S., which is a subsidy of Glenmark is said to have received the maximum number of approvals (18) from U.S. Food and Drug Administration (FDA or USFDA) in the previous year and Aurobindo received about 17 approvals. Sun Pharma and its subsidized company Taro Pharmaceuticals got about 15 approvals out of 19 in 2010.
Dr. Reddy's and Ranbaxy were the first companies to dominate the U.S .generic market for the past decade, but the recent statistics show a decline in their growth. Dr Reddy's had 17 approvals in 2009, but that number slumped to 11 in 2010. Ranbaxy, facing FDA regulatory issues for its two facilities in India for the past few years, had only seven approvals in 2009 and just three in 2010. Since a slump has just started projecting in their graphs, other Pharma companies are able to debut their products.
36 crore.
137 billion ($3 billion) in the 2009-10 financial year over the previous fiscal. Bio-pharma was the biggest contributor generating 60 percent of the industry's growth at 8,829 crore, followed by bio-services at 2,639 crore and bio-agri at 1,9According to data published by the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, the total turnover of India's pharmaceuticals is expected to reach $ 55 billion in 2020 from $ 12.6 billion in 2009. The report also states that the market has the further potential to reach $ 70 billion by 2020 in an aggressive growth scenario.Indian pharmaceutical companies like Glenmark, Aurobindo and Sun Pharma have not only carved a niche in the Indian market but also the U.S. as well. According to a report, they have bagged about 33 percent or 139 of 419 original Abbreviated New Drug Application (ANDA) approvals from the U.S. Food and Drug Administration (FDA) in 2010. These companies have bagged the first position in the U.S. generic market. Generics is the process of manufacturing cheaper versions of branded and patented drugs.
Glenmark Generics U.S., which is a subsidy of Glenmark is said to have received the maximum number of approvals (18) from U.S. Food and Drug Administration (FDA or USFDA) in the previous year and Aurobindo received about 17 approvals. Sun Pharma and its subsidized company Taro Pharmaceuticals got about 15 approvals out of 19 in 2010.
Dr. Reddy's and Ranbaxy were the first companies to dominate the U.S .generic market for the past decade, but the recent statistics show a decline in their growth. Dr Reddy's had 17 approvals in 2009, but that number slumped to 11 in 2010. Ranbaxy, facing FDA regulatory issues for its two facilities in India for the past few years, had only seven approvals in 2009 and just three in 2010. Since a slump has just started projecting in their graphs, other Pharma companies are able to debut their products.
36 crore.
No comments:
Post a Comment